Int J Angiol 2021; 30(03): 194-201
DOI: 10.1055/s-0041-1730446
Review Article

Left Main Coronary Artery Disease in Diabetics: Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting?

1   University of Kentucky College of Medicine, Lexington, Kentucky
,
2   Department of Cardiac Surgery, Ascension Saint Thomas Heart, Nashville, Tennessee
,
Meghna Ramaiah
3   University of Chicago, Chicago, Illinois
,
4   Division of Cardiothoracic Surgery, Department of Surgery, University of Kentucky College of Medicine, Lexington, Kentucky
› Institutsangaben

Abstract

The choice between coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for myocardial revascularization in patients with left main disease (LMD) is controversial. There is general agreement that CABG is appropriate for all patients, and PCI is acceptable for those with low-to-intermediate anatomic complexity. However, there is uncertainty about the relative safety and efficacy of PCI in patients with more complex LMD and with comorbidities such as diabetes. No direct comparison trial has focused on revascularization in diabetic patients with LMD, and thus conclusions on the topic are subject to the limitations of subgroup analysis, as well as the heterogeneous exclusion criteria, and methodologies of individual trials. The available evidence suggests that among diabetics, CABG is superior in patients with LMD with SYNTAX (SYNergy between percutaneous coronary intervention with TAXus and dardiac surgery) score greater than 33, distal bifurcation disease, or multivessel disease. PCI may be appropriate in those with less-extensive disease or those with limited life expectancy or high surgical risk.



Publikationsverlauf

Artikel online veröffentlicht:
31. August 2021

© 2021. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Rihal CS, Raco DL, Gersh BJ, Salim Y. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina. Circulation 2003; 108 (20) 2439-2445
  • 2 Iqbal J, Gunn J, Serruys PW. Coronary stents: historical development, current status and future directions. Br Med Bull 2013; 106: 193-211
  • 3 Patel MR, Calhoon JH, Dehmer GJ. et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. J Am Coll Cardiol 2017; 69 (17) 2212-2241
  • 4 Neumann F-J, Sousa-Uva M, Ahlsson A. et al; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40 (02) 87-165
  • 5 European Society of Cardiology. EACTS/ESC joint statement on the revision of the Guidelines on Myocardial Revascularization. Accessed April 28, 2021 at: https://www.escardio.org/The-ESC/Press-Office/Press-releases/EACTS-ESC-joint-statement-on-the-revision-of-the-Guidelines-on-Myocardial-Revascularization
  • 6 Thuijs DJFM, Kappetein AP, Serruys PW. et al; SYNTAX Extended Survival Investigators. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet 2019; 394 (10206): 1325-1334
  • 7 Lee K, Ahn JM, Yoon YH. et al. Long-term (10-year) outcomes of stenting or bypass surgery for left main coronary artery disease in patients with and without diabetes mellitus. J Am Heart Assoc 2020; 9 (08) e015372
  • 8 Milojevic M, Serruys PW, Sabik III JF. et al. Bypass surgery or stenting for left main coronary artery disease in patients with diabetes. J Am Coll Cardiol 2019; 73 (13) 1616-1628
  • 9 Park S-J, Park D-W. Diabetes in myocardial revascularization for left main coronary artery disease: predictor or decision maker?. J Am Coll Cardiol 2019; 73 (13) 1629-1632
  • 10 Hyun J, Kim JH, Jeong Y. et al; MAIN-COMPARE Registry. Long-term outcomes after PCI or CABG for left main coronary artery disease according to lesion location. JACC Cardiovasc Interv 2020; 13 (24) 2825-2836
  • 11 Stone GW, Kappetein AP, Sabik JF. et al; EXCEL Trial Investigators. Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med 2019; 381 (19) 1820-1830
  • 12 Ragosta M, Dee S, Sarembock IJ, Lipson LC, Gimple LW, Powers ER. Prevalence of unfavorable angiographic characteristics for percutaneous intervention in patients with unprotected left main coronary artery disease. Catheter Cardiovasc Interv 2006; 68 (03) 357-362
  • 13 Saha T, Naqvi SY, Goldberg S. Hybrid Revascularization: a review. Cardiology 2018; 140 (01) 35-44
  • 14 Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. Circulation 1983; 68 (05) 951-960
  • 15 Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation 1983; 68 (05) 939-950
  • 16 Caracciolo EA, Davis KB, Sopko G. et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 1995; 91 (09) 2335-2344
  • 17 Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978; 1 (8058): 263
  • 18 Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301 (02) 61-68
  • 19 Canfield J, Totary-Jain H. 40 years of percutaneous coronary intervention: history and future directions. J Pers Med 2018; 8 (04) E33
  • 20 Melly L, Torregrossa G, Lee T, Jansens J-L, Puskas JD. Fifty years of coronary artery bypass grafting. J Thorac Dis 2018; 10 (03) 1960-1967
  • 21 Diodato M, Chedrawy EG. Coronary artery bypass graft surgery: the past, present, and future of myocardial revascularisation. Surg Res Pract 2014; 2014: 726158
  • 22 Gaudino M, Ruel M, Obadia JF. et al. Methodologic considerations on four cardiovascular interventions trials with contradictory results. Ann Thorac Surg 2021; 111 (02) 690-699
  • 23 Ruel M, Falk V, Farkouh ME. et al. Myocardial revascularization trials. Circulation 2018; 138 (25) 2943-2951
  • 24 Gregson J, Stone GW, Ben-Yehuda O. et al. Implications of alternative definitions of peri-procedural myocardial infarction after coronary revascularization. J Am Coll Cardiol 2020; 76 (14) 1609-1621
  • 25 Ahmad Y, Howard JP, Arnold AD. et al. Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials. Eur Heart J 2020; 41 (34) 3228-3235
  • 26 Boudriot E, Thiele H, Walther T. et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J Am Coll Cardiol 2011; 57 (05) 538-545
  • 27 Akintoye E, Salih M, Olagoke O. et al. Intermediate and late outcomes with PCI vs CABG for left main disease - landmark meta-analysis of randomized trials. Cardiovasc Revasc Med 2020
  • 28 Kandzari DE, Gershlick AH, Serruys PW. et al. Procedural characteristics and clinical outcomes in patients undergoing percutaneous coronary intervention for left main trifurcation disease: the EXCEL trial. EuroIntervention 2020; 16 (12) e982-e988
  • 29 Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 2008; 31 (04) 714-719
  • 30 Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care 2007; 30 (03) 707-712
  • 31 Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54 (06) 1615-1625
  • 32 Laakso M. Heart in diabetes: a microvascular disease. Diabetes Care 2011; 34 (Suppl. 02) S145-S149
  • 33 Melidonis A, Dimopoulos V, Lempidakis E. et al. Angiographic study of coronary artery disease in diabetic patients in comparison with nondiabetic patients. Angiology 1999; 50 (12) 997-1006
  • 34 Corpus RA, George PB, House JA. et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004; 43 (01) 8-14
  • 35 Tanaka N, Terashima M, Rathore S. et al. Different patterns of vascular response between patients with or without diabetes mellitus after drug-eluting stent implantation: optical coherence tomographic analysis. JACC Cardiovasc Interv 2010; 3 (10) 1074-1079
  • 36 Loutfi M, Sadaka MA, Sobhy M. Outcomes of DES in diabetic and nondiabetic patients with complex coronary artery disease after risk stratification by the SYNTAX Score. Clin Med Insights Cardiol 2016; 10: 103-110
  • 37 Santos KAQ, Berto B, Sousa AG, Costa FA. Prognosis and complications of diabetic patients undergoing isolated coronary artery bypass surgery. Rev Bras Cir Cardiovasc 2016; 31 (01) 7-14
  • 38 Momin AU, Deshpande R, Potts J. et al. Incidence of sternal infection in diabetic patients undergoing bilateral internal thoracic artery grafting. Ann Thorac Surg 2005; 80 (05) 1765-1772 , discussion 1772
  • 39 Agrifoglio M, Trezzi M, Barili F. et al. Double vs single internal thoracic artery harvesting in diabetic patients: role in perioperative infection rate. J Cardiothorac Surg 2008; 3: 35
  • 40 Dorman MJ, Kurlansky PA, Traad EA, Galbut DL, Zucker M, Ebra G. Bilateral internal mammary artery grafting enhances survival in diabetic patients: a 30-year follow-up of propensity score-matched cohorts. Circulation 2012; 126 (25) 2935-2942
  • 41 Taggart DP, Altman DG, Gray AM. et al; ART Investigators. Randomized trial of bilateral versus single internal-thoracic-artery grafts. N Engl J Med 2016; 375 (26) 2540-2549
  • 42 Deo SV, Shah IK, Dunlay SM. et al. Bilateral internal thoracic artery harvest and deep sternal wound infection in diabetic patients. Ann Thorac Surg 2013; 95 (03) 862-869
  • 43 Peterson MD, Borger MA, Rao V, Peniston CM, Feindel CM. Skeletonization of bilateral internal thoracic artery grafts lowers the risk of sternal infection in patients with diabetes. J Thorac Cardiovasc Surg 2003; 126 (05) 1314-1319
  • 44 Gaudino M, Benedetto U, Fremes S. et al; RADIAL Investigators. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery. N Engl J Med 2018; 378 (22) 2069-2077
  • 45 BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 2007; 49 (15) 1600-1606
  • 46 Frye RL, August P, Brooks MM. et al; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360 (24) 2503-2515
  • 47 Farooq V, van Klaveren D, Steyerberg EW. et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 2013; 381 (9867): 639-650
  • 48 Farkouh ME, Domanski M, Sleeper LA. et al; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367 (25) 2375-2384
  • 49 Head SJ, Milojevic M, Daemen J. et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 2018; 391 (10124): 939-948
  • 50 Tam DY, Dharma C, Rocha R. et al. Long-term survival after surgical or percutaneous revascularization in patients with diabetes and multivessel coronary disease. J Am Coll Cardiol 2020; 76 (10) 1153-1164
  • 51 Abdallah MS, Wang K, Magnuson EA. et al; SYNTAX Trial Investigators. Quality of life after Surgery or DES in patients with 3-vessel or left main disease. J Am Coll Cardiol 2017; 69 (16) 2039-2050
  • 52 Puskas JD, Kilgo PD, Thourani VH. et al. The society of thoracic surgeons 30-day predicted risk of mortality score also predicts long-term survival. Ann Thorac Surg 2012; 93 (01) 26-33 , discussion 33–35
  • 53 Kirtane AJ, Doshi D, Leon MB. et al. Treatment of higher-risk patients with an indication for revascularization: evolution within the field of contemporary percutaneous coronary intervention. Circulation 2016; 134 (05) 422-431
  • 54 Farmer SA, Lenzo J, Magid DJ. et al. Hospital-level variation in use of cardiovascular testing for adults with incident heart failure: findings from the cardiovascular research network heart failure study. JACC Cardiovasc Imaging 2014; 7 (07) 690-700
  • 55 Kuno T, Takagi H, Ando T. et al. Safety and efficacy of mechanical circulatory support with Impella or intra-aortic balloon pump for high-risk percutaneous coronary intervention and/or cardiogenic shock: Insights from a network meta-analysis of randomized trials. Catheter Cardiovasc Interv 2020
  • 56 Shamekhi J, Pütz A, Zimmer S. et al. Impact of hemodynamic support on outcome in patients undergoing high-risk percutaneous coronary intervention. Am J Cardiol 2019; 124 (01) 20-30
  • 57 Meraj PM, Dixon S, Moses J. et al. Nonemergent percutaneous coronary intervention on an unprotected left main coronary artery supported with Impella heart pump in patients ineligible for surgical revascularization. J Interv Cardiol 2019; 2019: 9691753
  • 58 Schreiber T, Wah Htun W, Blank N. et al. Real-world supported unprotected left main percutaneous coronary intervention with impella device; data from the USpella registry. Catheter Cardiovasc Interv 2017; 90 (04) 576-581
  • 59 ABIOMED Heart Recovery. Ongoing and Upcoming trials. Accessed January 14, 2021 at: https://www.protectedpci.com/clinical-research/
  • 60 Green KD, Lynch Jr DR, Chen TP, Zhao D. Combining PCI and CABG: the role of hybrid revascularization. Curr Cardiol Rep 2013; 15 (04) 351
  • 61 Puskas JD, Halkos ME, DeRose JJ. et al. Hybrid coronary revascularization for the treatment of multivessel coronary artery disease: a multicenter observational study. J Am Coll Cardiol 2016; 68 (04) 356-365
  • 62 Takaro T, Hultgren HN, Lipton MJ, Detre KM. The VA cooperative randomized study of surgery for coronary arterial occlusive disease II. Subgroup with significant left main lesions. Circulation 1976; 54 (6, suppl): III107-III117
  • 63 European Coronary Surgery Study Group. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Lancet 1982; 2 (8309): 1173-1180
  • 64 Hueb WA, Bellotti G, de Oliveira SA. et al. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol 1995; 26 (07) 1600-1605
  • 65 Calafiore AM, Giammarco GD, Teodori G. et al. Left anterior descending coronary artery grafting via left anterior small thoracotomy without cardiopulmonary bypass. Ann Thorac Surg 1996; 61 (06) 1658-1663 , discussion 1664–1665
  • 66 Eagle KA, Guyton RA, Davidoff R. et al; American College of Cardiology/American Heart Association. ACC/AHA guidelines for coronary artery bypass graft surgery. J Am Coll Cardiol 1999; 34 (04) 1262-1347
  • 67 Kolh P, Wijns W, Danchin N. et al; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI). Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2010; 38 (Suppl): S1-S52
  • 68 Levine GN, Bates ER, Blankenship JC. et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124 (23) e574-e651
  • 69 Windecker S, Kolh P, Alfonso F. et al; Authors/Task Force members. 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35 (37) 2541-2619
  • 70 European Association of Cardio-Thoracic Surgery.. Changing evidence. Accessed January 21, 2021 at: https://www.eacts.org/changing-evidence-changing-practice/
  • 71 Park D-W, Kim Y-H, Yun S-C. et al. Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. J Am Coll Cardiol 2010; 56 (17) 1366-1375
  • 72 Buszman PE, Buszman PP, Banasiewicz-Szkróbka I. et al. Left main stenting in comparison with surgical revascularization: 10-year outcomes of the (Left Main Coronary Artery Stenting) LE MANS trial. JACC Cardiovasc Interv 2016; 9 (04) 318-327
  • 73 Holm NR, Mäkikallio T, Lindsay MM. et al; NOBLE investigators. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet 2020; 395 (10219): 191-199
  • 74 Park S-J, Kim Y-H, Park D-W. et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011; 364 (18) 1718-1727
  • 75 Yu X, He J, Luo Y. et al. Influence of diabetes mellitus on long-term outcomes of patients with unprotected left main coronary artery disease treated with either drug-eluting stents or coronary artery bypass grafting. Int Heart J 2015; 56 (01) 43-48